Congratulations to Ph.D. Candidate Lisa Welter on being chosen to receive an American Association for Cancer Research (AACR) Scholar-in-Training Award! Her abstract entitled "Characterization of disease evolution in sequential sampled metastatic breast cancer using liquid biopsy" was selected from a large candidate pool and will support her attending the 2018 AACR Annual Meeting.
The review “Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation” by Keating and colleagues is now published in Clin Transl Sci. In this article, the challenges encountered with newly evolving high-content measurement systems are illustrated with examples of two platforms: our High Definition Single Cell Analysis (HD-SCA) workflow, optimized for identifying and characterizing rare cells in liquid biopsy samples, and the MultiOmyx Immunofluorescence (MxIF), for enabling “hyperplexed” measurements of proteins and nucleic acids in single cells or in tissues.
“The platforms profiled here are examples of instruments that translate high-content information out of the research laboratory to the clinical research setting for characterization and monitoring of single cells in tissue or blood. They go beyond enumeration of assay end points to enable profiling of heterogeneous cell populations. As such, the systems could be exploited in the drug development and clinical arenas not only for in vitro evaluations guiding clinical decisions, but also ex vivo studies, such as assessing target activity, probing for clinically relevant targets, and characterizing cancer cell and tumor heterogeneity.”
The study “Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry” by E. Gerdtsson and colleagues, published in January by Convergent Science Physical Oncology, established the proof of concept for the metal-detection technique, which allows scientists to see circulating and disseminated tumor cells at a molecular level in a way not possible before. The new approach of using metal-tagged antibodies and a laser ablation system, coupled with a mass spectrometer, gives scientists the ability to track 35 different metal labels simultaneously. Because of proof-of-concept studies like this, the technique is now an official product of Fluidigm and is available for researchers worldwide.
The Oncotype DX® AR-V7 Nucleus Detect™ test was developed by Epic Sciences to help prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells. Findings from the first validation study were published in JAMA Oncology in 2016. Results from the second validation study were presented at the 2018 Genitourinary Cancers Symposium of the American Society of Clinical Oncology.
Through a blood draw, the test detects AR-V7 protein in the nucleus of circulating tumor cells utilizing Epic Sciences' No Cell Left Behind® platform to accurately identify patients who are resistant to androgen receptor–targeted therapies and who should instead switch to chemotherapy. The test is now commercially available via Epic Sciences at its centralized, CLIA-certified laboratory in San Diego.
Ben Ormseth was awarded the Wattis Dumke Undergraduate Research Fellowship by The USC Dornsife College of Letters, Arts and Sciences Department of Biological Sciences. Congratulations!
A major goal of this program is to provide financial assistance for undergraduate students in majors within the Biological Sciences who might otherwise not be able to participate in laboratory research because they need to work on or off campus to cover educational expenses.
Ben will work on the validation of a new staining protocol for the HD-SCA workflow.
The work “Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer” by Prof. James Hicks and colleagues at Cold Spring Harbor Laboratory is now published in Cancer Research. The publication describes the utility of single-cell genomics from prostate biopsies towards improving diagnosis and prognosis in prostate cancer.
Read the full article at http://cancerres.aacrjournals.org/content/78/2/348
A distinction between indolent and aggressive disease is a major challenge in diagnostics of prostate cancer. As genetic heterogeneity and complexity may influence clinical outcome, we have initiated studies on single tumor cell genomics. In this study, we demonstrate that sparse DNA sequencing of s...